OrbiMed’s Madrigal Pharmaceuticals MDGL Stock Holding History

OrbiMed’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-253,309	Closed	-$37M	–	127
2023 Q3	$37M	Sell	253,309 -68,260	-21%	-$12.8M	0.79%	47
2023 Q2	$74.3M	Buy	+321,569	New	+$87.1M	1.35%	27

Other funds holding MDGL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed's MDGL Position: Q4 2023 in Review

OrbiMed sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2023, closing a stake of 253,309 shares — an estimated $37M sold.

OrbiMed first reported a position in MDGL in Q2 2023 and held it in 2 quarters. The position peaked at $74.3M in Q2 2023. 226 funds tracked by Wall St. Rank hold MDGL as of Q4 2023.

OrbiMed reported no remaining Madrigal Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
OrbiMed sold 253,309 Madrigal Pharmaceuticals shares in Q4 2023, an estimated $37M.
OrbiMed first reported a position in Madrigal Pharmaceuticals in Q2 2023 and held it in 2 quarters.
OrbiMed's Madrigal Pharmaceuticals position peaked at $74.3M in Q2 2023.
226 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.